dnase
Deoxyribonuclease refers to a group of glycoprotein endonucleases which are enzymes that catalyze the hydrolytic cleavage of phosphodiester linkages in the DNA backbone, thus degrading DNA. The role of the DNase enzyme in cells includes breaking down extracellular DNA (ecDNA) excreted by apoptosis, necrosis, and neutrophil extracellular traps (NET) of cells to help reduce inflammatory responses that otherwise are elicited. A wide variety of deoxyribonucleases are known and fall into one of two families, which differ in their substrate specificities, chemical mechanisms, and biological functions. Laboratory applications of DNase include purifying proteins when extracted from prokaryotic organisms. Additionally, DNase has been applied as a treatment for diseases that are caused by ecDNA in the blood plasma. Assays of DNase are emerging in the research field as well. — Wikipedia
Clinical trial activity
11 trials · 14 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 2015 (NCT02605590)
Timeline
Indications
Approved for
Mechanism of action
- PlasminogenACTIVATOR
PLG activator
- Deoxyribonuclease-1INHIBITOR
DNASE1 inhibitor
- Deoxyribonuclease-1Supplementation
DNASE1 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDeoxyribonuclease ↗
Also known as
- alidornase alfa
- dnase
- dnase
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05453695 | Phase 1 | Oct 31, 2022 | Canadian Institutes of Health Research (CIHR), McMaster University |
| NCT06139835 | N/A | Jun 8, 2022 | Pontis Biologics, Inc. |
| NCT04409925 | Phase 1 | Jun 30, 2020 | Exactis Innovation, Hamilton Health Sciences Corporation, McGill University, Roche |
| NCT04541979 | Phase 2 | Jun 4, 2020 | Region Skane |
| NCT04445285 | Phase 2 | Apr 28, 2020 | University of South Alabama |
| NCT03994380 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2019 | University of Colorado, Denver |
| NCT03468933 | Phase 4 | Nov 1, 2017 | Tulane University |
| NCT03213834 | Phase 4 | Sep 14, 2017 | University of Florida |
| NCT03167281 | Phase 4 | Feb 17, 2017 | University of South Carolina |
| NCT02722122 | Phase 2 | May 1, 2016 | Protalix |
| NCT02605590 | Phase 1 | Dec 1, 2015 | Protalix |
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Protalix | For profit | 2 | 2 | 2 | 2015 |
| Canadian Institutes of Health Research (CIHR) | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Exactis Innovation | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Hamilton Health Sciences Corporation | Academic/Hospital | 1 | 0 | 1 | 2020 |
| McGill University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| McMaster University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Pontis Biologics, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Region Skane | Government | 1 | 1 | 1 | 2020 |
| Roche | For profit | 1 | 0 | 1 | 2020 |
| Tulane University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Florida | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of South Alabama | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of South Carolina | Academic/Hospital | 1 | 1 | 1 | 2017 |